Are you over 18 and want to see adult content?
More Annotations
A complete backup of odyssey-com.co.jp
Are you over 18 and want to see adult content?
A complete backup of ashpublications.org
Are you over 18 and want to see adult content?
A complete backup of plethorathemes.com
Are you over 18 and want to see adult content?
A complete backup of nurturestore.co.uk
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://iro38.ru
Are you over 18 and want to see adult content?
A complete backup of https://izolyatsia.org
Are you over 18 and want to see adult content?
A complete backup of https://sony-optiarc.eu
Are you over 18 and want to see adult content?
A complete backup of https://winchcombemedical.nhs.uk
Are you over 18 and want to see adult content?
A complete backup of https://thelovelyplants.com
Are you over 18 and want to see adult content?
A complete backup of https://derbyshire.gov.uk
Are you over 18 and want to see adult content?
A complete backup of https://dokter.nl
Are you over 18 and want to see adult content?
A complete backup of https://statisticsdonewrong.com
Are you over 18 and want to see adult content?
A complete backup of https://armoredpenguin.com
Are you over 18 and want to see adult content?
A complete backup of https://cjcoatings.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://pippodelbono.it
Are you over 18 and want to see adult content?
Text
EVALUATE
Immuno-oncology combination trials triple since 2015 Keytruda now partner of choice. This report examines the explosion in the number of clinical trials using anti-PD-1 and anti-PD-L1 antibodies combined with other therapeutic approaches. WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 Worldwide medtech sales forecast to reach $595bn by 2024. The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –June 2016
EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR ofBIOSIMILAR ANALYSIS
Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –October 2016
EVALUATEPHARMA WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2016, Outlook to 2022 9th Edition –September 2016
EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. BRAZIL MARKET LANDSCAPE Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
EVALUATE
Immuno-oncology combination trials triple since 2015 Keytruda now partner of choice. This report examines the explosion in the number of clinical trials using anti-PD-1 and anti-PD-L1 antibodies combined with other therapeutic approaches. WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 Worldwide medtech sales forecast to reach $595bn by 2024. The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –June 2016
EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR ofBIOSIMILAR ANALYSIS
Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –October 2016
EVALUATEPHARMA WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2016, Outlook to 2022 9th Edition –September 2016
EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. BRAZIL MARKET LANDSCAPE Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 Worldwide medtech sales forecast to reach $595bn by 2024. The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 Key Highlights. Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024) R&D spend is forecast at 16.9% of prescription sales in 2024 EVALUATEPHARMA WORLD PREVIEW 2019, OUTLOOK TO 2024 Foreword 3 The EvaluatePharma® World Preview 2019 comes at one of the most exciting points in the industry’s development. The convergence of tech and health is becoming reality, while the promise of cell and gene therapy is finally being EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 EvaluatePharma ® World Preview 2018, Outlook to 2024 Executive Summary 11th Edition – June 2018 EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 EvaluatePharma® World Preview 2018 Inforgraphic – JUNE 2018 Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –June 2017
BIOSIMILAR ANALYSIS
Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 Analysis Highlights • Worldwide prescription drug sales forecasted to grow at a robust 6.5% (CAGR) through 2022 to reach $1.06trn • 32% of the 2022 increase in sales to come from orphan drugs (+$95bn) WORLD PREVIEW 2014, OUTLOOK TO 2020 F or the first time in the pharmaceutical industry’s history, the consensus forecast of worldwide prescription drug sales is set to exceed one trillion dollars, reaching $1,017bn by 2020, equating to an BRAZIL MARKET LANDSCAPE Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 Key Highlights. Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024) Oncology continues to be a key industry driver, with a forecasted CAGR of 12% from 2017 to 2024. Novartis will be the leading prescription drug company in 2024 with sales of $53.2bn. Humira remains the top selling drug in 2024, despite a CAGRof -3%
EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –June 2016
EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –June 2017
EVALUATEMEDTECH WORLD PREVIEW 2015, OUTLOOK TO 2020 EvaluateMedTech ® World Preview 2015, Outlook to 2020 4th Edition –October 2015
EVALUATEPHARMA WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2016, Outlook to 2022 9th Edition –September 2016
EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 WWW Download our Report www.evaluate.com/ MedtechWorldPreview2016 www.evaluate.com Evaluate is the trusted provider of commercial intelligence including BRAZIL MARKET LANDSCAPE Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 Key Highlights. Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024) Oncology continues to be a key industry driver, with a forecasted CAGR of 12% from 2017 to 2024. Novartis will be the leading prescription drug company in 2024 with sales of $53.2bn. Humira remains the top selling drug in 2024, despite a CAGRof -3%
EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –June 2016
EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –June 2017
EVALUATEMEDTECH WORLD PREVIEW 2015, OUTLOOK TO 2020 EvaluateMedTech ® World Preview 2015, Outlook to 2020 4th Edition –October 2015
EVALUATEPHARMA WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2016, Outlook to 2022 9th Edition –September 2016
EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 WWW Download our Report www.evaluate.com/ MedtechWorldPreview2016 www.evaluate.com Evaluate is the trusted provider of commercial intelligence including BRAZIL MARKET LANDSCAPE Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
EVALUATE
Key Highlights: There are now 268 combination trials involving Keytruda and 242 with Opdivo, of which 86 combine Opdivo with Yervoy. Keytruda’s dominance comes as the drug continues to impress in clinical trials. The number of studies combining anti-PD-1/PD-L1s with chemotherapy have surged, potentially spurred by Roche’s effortswith
EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). Medtronic is forecast to continue to be the leading medtech company in 2024 with sales of $39 billion. The EvaluateMedTech World Preview 2018highlights
EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 Key Highlights. Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024) Oncology continues to be a key industry driver, with a forecasted CAGR of 12% from 2017 to 2024. Novartis will be the leading prescription drug company in 2024 with sales of $53.2bn. Humira remains the top selling drug in 2024, despite a CAGRof -3%
PD-1 / PD-L1 COMBINATION THERAPIES IDO inhibitors, which are not MAbs but small-molecule agents that affect T-cell activation by halting tryptophan breakdown, deserve aspecial mention.
EP VANTAGE 2018 PREVIEW EP Vantage 2018 Preview Amy Brown, Edwin Elmhirst and Jon Gardner –December 2017
EVALUATEPHARMA WORLD PREVIEW 2015, OUTLOOK TO 2020 EvaluatePharma ® World Preview 2015, Outlook to 2020 8th Edition –June 2015
BIOSIMILAR ANALYSIS
Biosimilar Analysis Biological Patent Expiries Biosimilars are expected to increasingly challenge branded biologicals in coming years Total of $87.4 billion of branded biological sales BRAZIL MARKET LANDSCAPE Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 WWW Download our Report www.evaluate.com/ MedtechWorldPreview2016 www.evaluate.com Evaluate is the trusted provider of commercial intelligence including JAPAN SALES, VOLUME, PRICING 2015 EvaluatePharma®’s Japan Sales, Volume, Pricing Intelligence The size of the Japanese pharmaceutical market and the favourable payer environment makes it aEVALUATE
Key Highlights: There are now 268 combination trials involving Keytruda and 242 with Opdivo, of which 86 combine Opdivo with Yervoy. Keytruda’s dominance comes as the drug continues to impress in clinical trials. The number of studies combining anti-PD-1/PD-L1s with chemotherapy have surged, potentially spurred by Roche’s effortswith
EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). Medtronic is forecast to continue to be the leading medtech company in 2024 with sales of $39 billion. The EvaluateMedTech World Preview 2018highlights
WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –June 2016
EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –October 2016
EVALUATEPHARMA WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2016, Outlook to 2022 9th Edition –September 2016
EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –June 2017
EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. BRAZIL MARKET LANDSCAPE Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
EVALUATE
Key Highlights: There are now 268 combination trials involving Keytruda and 242 with Opdivo, of which 86 combine Opdivo with Yervoy. Keytruda’s dominance comes as the drug continues to impress in clinical trials. The number of studies combining anti-PD-1/PD-L1s with chemotherapy have surged, potentially spurred by Roche’s effortswith
EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). Medtronic is forecast to continue to be the leading medtech company in 2024 with sales of $39 billion. The EvaluateMedTech World Preview 2018highlights
WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –June 2016
EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –October 2016
EVALUATEPHARMA WORLD PREVIEW 2016, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2016, Outlook to 2022 9th Edition –September 2016
EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –June 2017
EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. BRAZIL MARKET LANDSCAPE Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024 The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). Medtronic is forecast to continue to be the leading medtech company in 2024 with sales of $39 billion. The EvaluateMedTech World Preview 2018highlights
EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 Key Highlights. Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024) Oncology continues to be a key industry driver, with a forecasted CAGR of 12% from 2017 to 2024. Novartis will be the leading prescription drug company in 2024 with sales of $53.2bn. Humira remains the top selling drug in 2024, despite a CAGRof -3%
EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 EvaluatePharma ® World Preview 2018, Outlook to 2024 Executive Summary 11th Edition – June 2018 EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 EvaluatePharma® World Preview 2018 Inforgraphic – JUNE 2018 Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 Analysis Highlights • Worldwide prescription drug sales forecasted to grow at a robust 6.5% (CAGR) through 2022 to reach $1.06trn • 32% of the 2022 increase in sales to come from orphan drugs (+$95bn) WORLD PREVIEW 2014, OUTLOOK TO 2020 F or the first time in the pharmaceutical industry’s history, the consensus forecast of worldwide prescription drug sales is set to exceed one trillion dollars, reaching $1,017bn by 2020, equating to anBIOSIMILAR ANALYSIS
Biosimilar Analysis Biological Patent Expiries Biosimilars are expected to increasingly challenge branded biologicals in coming years Total of $87.4 billion of branded biological sales ORPHAN DRUG REPORT 2014 Welcome to the EvaluatePharma® Orphan Drug Report 2014 The second edition of EvaluatePharma’s Orphan Drug Report brings together many of our analyses to provide top-level insight, from the world’s financial markets, into the expected EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022 WWW Download our Report www.evaluate.com/ MedtechWorldPreview2016 www.evaluate.com Evaluate is the trusted provider of commercial intelligence including BRAZIL MARKET LANDSCAPE Evaluate Headquarters Evaluate Ltd. 11-29 Fashion Street London E1 6PX United Kingdom T +44 (0)20 7377 0800 F +44 (0)20 7539 1801 EvaluateNorth America
EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024EVALUATEMEDTECH WORLD PREVIEW 2019EVALUATEPHARMA WORLD PREVIEW 2018EVALUATEPHARMAWORLD PREVIEW 2020
The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). Medtronic is forecast to continue to be the leading medtech company in 2024 with sales of $39 billion. The EvaluateMedTech World Preview 2018highlights
WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) ORPHAN DRUG REPORT 2018 Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024. Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by 2024. By 2024, orphan drugs will represent over a fifth of theworldwide
EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –June 2016
EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022. The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn. EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years. The new edition of our annual report, EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that i ncreased scrutiny around the pricing of medicines is starting to have on drug sales growth. Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022EVALUATEMEDTECH WORLD PREVIEWEVALUATEMEDTECH WORLD PREVIEW 2019 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –October 2016
EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –June 2017
BUDGET-BUSTERS: THE SHIFT TO HIGH-PRICED INNOVATOR DRUGS EvaluatePharma® Foreword: Move to Higher Priced Drugs Within the Top 100 Selling Drugs in the USA Over the last five years a fundamental shift in spending trends towards high-priced medicines, EVALUATEMEDTECH WORLD PREVIEW 2018, OUTLOOK TO 2024EVALUATEMEDTECH WORLD PREVIEW 2019EVALUATEPHARMA WORLD PREVIEW 2018EVALUATEPHARMAWORLD PREVIEW 2020
The new edition of the EvaluateMedTech World Preview is now available. The report shows that the medical device and diagnostics industry will reach $595 billion in sales by 2024 (CAGR of 5.6%). Medtronic is forecast to continue to be the leading medtech company in 2024 with sales of $39 billion. The EvaluateMedTech World Preview 2018highlights
WORLD PREVIEW 2018, OUTLOOK TO 2024 Foreword 4 In the 2018 edition of the EvaluateMedTech® World Preview we can reveal that the global medtech industry is expected to grow at 5.6% per year (CAGR) ORPHAN DRUG REPORT 2018 Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024. Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by 2024. By 2024, orphan drugs will represent over a fifth of theworldwide
EUROPEAN PHARMA MARKET OUTLOOK TO 2022 European Pharma Market Outlook to 2022 Top selling marketed products in 2022 Size of the market in EU-5 set to grow by 25% between 2017-2022 with a CAGR of SHIFTING CAR-TS INTO A HIGHER GEAR Shifting CAR-Ts Into a Higher Gear Jacob Plieth & Edwin Elmhirst –June 2016
EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022. The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn. EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years. The new edition of our annual report, EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that i ncreased scrutiny around the pricing of medicines is starting to have on drug sales growth. Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from EVALUATEMEDTECH WORLD PREVIEW 2016, OUTLOOK TO 2022EVALUATEMEDTECH WORLD PREVIEWEVALUATEMEDTECH WORLD PREVIEW 2019 EvaluateMedTech ® World Preview 2016, Outlook to 2022 5th Edition –October 2016
EVALUATEPHARMA WORLD PREVIEW 2017, OUTLOOK TO 2022 EvaluatePharma ® World Preview 2017, Outlook to 2022 10th Edition –June 2017
BUDGET-BUSTERS: THE SHIFT TO HIGH-PRICED INNOVATOR DRUGS EvaluatePharma® Foreword: Move to Higher Priced Drugs Within the Top 100 Selling Drugs in the USA Over the last five years a fundamental shift in spending trends towards high-priced medicines,EVALUATE
Key Highlights: There are now 268 combination trials involving Keytruda and 242 with Opdivo, of which 86 combine Opdivo with Yervoy. Keytruda’s dominance comes as the drug continues to impress in clinical trials. The number of studies combining anti-PD-1/PD-L1s with chemotherapy have surged, potentially spurred by Roche’s effortswith
EVALUATEPHARMA WORLD PREVIEW 2018, OUTLOOK TO 2024 Key Highlights. Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024) Oncology continues to be a key industry driver, with a forecasted CAGR of 12% from 2017 to 2024. Novartis will be the leading prescription drug company in 2024 with sales of $53.2bn. Humira remains the top selling drug in 2024, despite a CAGRof -3%
EVALUATEMEDTECH WORLD PREVIEW 2017, OUTLOOK TO 2022 Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022. The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn. YOUR COMMERCIAL LENS ON THE PHARMACEUTICAL INDUSTRY EvaluatePharma gives you the time and confidence to turn knowledge into insight, and insight into action Comprehensive commercial data EvaluatePharma is your most comprehensive source of commercial information on the past, present and EVALUATEMEDTECH WORLD PREVIEW 2015, OUTLOOK TO 2020 EvaluateMedTech ® World Preview 2015, Outlook to 2020 4th Edition –October 2015
PHARMACEUTICAL INNOVATION IN EUROPE Two factors are at play behind the projected impact of new therapies: 1. A new stream of potential medical breakthroughs which are likely to transform many therapy areas. Oncology – driven by the uptake of PD-1/PD-L1 inhibitors (e.g. Opdivo, Keytruda) – is going through a medical revolution that is likely to re-shape the current clinicalguidelines.
EP VANTAGE 2018 PREVIEW EP Vantage 2018 Preview Amy Brown, Edwin Elmhirst and Jon Gardner –December 2017
WORLD PREVIEW 2014, OUTLOOK TO 2020 F or the first time in the pharmaceutical industry’s history, the consensus forecast of worldwide prescription drug sales is set to exceed one trillion dollars, reaching $1,017bn by 2020, equating to an WORLD PREVIEW 2014, OUTLOOK TO 2020 The third edition of the EvaluateMedTech® World Preview reveals that the medtech market is expected to grow at 5% per year (CAGR) between 2013 and 2020, achieving global sales of $514bn in 2020 (page 6). The analysis is based on in-depth forecast models for the ORPHAN DRUG REPORT 2014 Welcome to the EvaluatePharma® Orphan Drug Report 2014 The second edition of EvaluatePharma’s Orphan Drug Report brings together many of our analyses to provide top-level insight, from the world’s financial markets, into the expected Skip to main content* Contact Us __ __
* Sign Up
* Subscriber Sign In ____ Switch language
* " class="en is-active">">English * " class="ja">">JapaneseNAVIGATION
サイト内検索
__
*
COVID-19
* COVID-19 Update
* Evaluate Vantage COVID-19 Report * COVID-19 Stories from Evaluate Vantage * Evaluate’s Business Continuity Plan*
What We Do
* Commercial Intelligence*
Products
* EvaluatePharma
* Evaluate Omnium
* Japan Drug Forecasts * European Drug Forecasts* Epi Analyzer
* Evaluate Custom Solutions*
Evaluate Vantage
* News
* Analysis
* Policy & Pricing
* Data Insights
* Events
* Medtech
* Therapy Areas
* Editorial Team
* About Evaluate Vantage*
How We Can Help You
* Pharma and Biotech* Medtech
* Financial Services * Management Consultancies* Service Providers
* Customer Testimonials * Thought Leadership*
About Us
* Press Releases
* Media Coverage
* Executive Team
* Vision & History
*
Careers
* Current Vacancies
* Contact Us
* Sign Up for Evaluate Vantage * Subscriber Sign InSearch
__
HOW DO YOU ACCURATELY ANALYSE ALL OF THE DRUGS THAT ARE BEING DEVELOPED WHEN IN EVERY 20 ONLY ONE WILL MAKE IT TO THE MARKET PLACE ?Learn More
EVALUATE RADICALLY TRANSFORMS YOUR CONFIDENCE IN STRATEGIC PORTFOLIODECISIONS.
When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support. Evaluate provides a complete and dynamic valuation of pharma assets, turning understanding into insight, and insight into action.How we can help you
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.OK
Market Reports
Thought Leadership
Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual EvaluatePharma World Preview.More
OUR PRODUCTS
EvaluatePharma
Get a global view of the pharmaceutical market’s past, present and future performance with over two decades of commercial data and consensus forecasts to 2026.More
OUR SERVICES
Custom Solutions
Improve your strategic decision-making with customised, data-driven solutions that draw on our collaborative team of industry experts and trusted commercial intelligence.More
Independent, data-driven daily news and analysis on pharma, biotechand medtech.
November 20, 2020
ASH 2020 PREVIEW – LATE-BREAKER PUTS UNIQURE IN POLE POSITION Among the upcoming haematology meeting’s non-oncology presentations Uniqure’s haemophilia B gene therapy scores a valuable late-breaker.November 20, 2020
J&J TRIES TO STRIKE THE RIGHT NOTE WITH OTTAVA But launch is unlikely before 2024.November 19, 2020
THE WAIT FOR ASTRAZENECA’S PIVOTAL COVID-19 VACCINE DATANovember 19, 2020
SOME OF BIOPHARMA’S BIGGEST ASSETS FACE A SOLO EXISTENCENovember 18, 2020
DRUG REJECTIONS RISE AS COVID-19 BITES Independent, data-driven daily news and analysis on pharma, biotechand medtech.
Sign up
Open modal
Evaluate HQ
44-(0)20-7377-0800
Evaluate Americas
+1-617-573-9450
Evaluate APAC
+81-(0)80-1164-4754
FOOTER MENU
* Terms and Conditions* Privacy Policies
* Cookie Policy
* __
* __
* __
© Copyright 2020 Evaluate Ltd.Tweet
Share
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0